Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2008-10-02 Report Publication Anno…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is very short (1672 characters) and explicitly states that an attached report concerns the postponement of an Extraordinary General Meeting (EGM). The key phrase is: "Attached hereto is a report on *Extraordinary General Meetings Postponed Until October 10, 2008*". This structure—announcing the publication of a specific document related to a meeting—fits the definition of a Report Publication Announcement (RPA) rather than the AGM material itself (AGM-R) or a proxy statement (PSI). The content relates directly to a general meeting, but the document's function is to announce the postponement report.
2008-10-02 English
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the postponement of Extraordinary General Meetings (EGMs) of XTL Biopharmaceuticals Ltd. It provides details about the new date and location of the meetings and voting procedures. There is no financial data, no report attached or referenced as being published, and no detailed meeting materials included. The content is focused on the scheduling and procedural aspects of the shareholder meetings, which fits the category of announcements related to shareholder meetings but not the actual meeting materials or voting results. Since it is about the postponement of EGMs, it is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like AGM Information or Declaration of Voting Results.
2008-10-02 Hebrew (modern)
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is very short (1672 characters) and explicitly states that an attached report concerns an 'Extraordinary General Meetings Postponed Until October 10, 2008' with a filename 'PostponedEGM10208-Final_isa.pdf'. This structure—announcing the postponement of a meeting and attaching the relevant document—fits the definition of an announcement regarding a meeting, rather than the meeting materials themselves (AGM-R) or a proxy solicitation (PSI). Since the postponement relates to a General Meeting, and the document is an announcement of an event/status change rather than the full meeting presentation or voting results, it is best classified as a general Regulatory Filing (RNS) or potentially related to AGM information. Given the context of postponement and the short nature, RNS is the most appropriate fallback for a specific regulatory update that isn't a standard financial report or a formal voting result declaration (DVA). However, since it directly concerns an Extraordinary General Meeting (EGM), and AGM-R covers AGM materials, RNS serves as the best fit for this specific announcement type that isn't a core financial filing.
2008-10-02 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It announces the postponement of Extraordinary General Meetings (EGMs) due to lack of quorum and provides details about the rescheduled meetings. The document is relatively short (3260 characters) and primarily serves as an announcement rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis, nor is it a proxy solicitation or voting results announcement. Given the nature of the content—an announcement about the scheduling of shareholder meetings—and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2008-10-02 English
Regulatory Filings 2008
Regulatory Filings
2008-09-12 English
Immediate Report
Director's Dealing Classification · 100% confidence The document is a Form 3 filed with the SEC, which is an Initial Statement of Beneficial Ownership of Securities. It reports insider ownership details such as shares and options held by a director or officer. This type of filing is related to insider transactions and ownership disclosures by company directors or executives. It is not an earnings release, annual report, or any other financial or management report. It specifically matches the description of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4020 characters, which is typical for such filings. Therefore, the correct classification is Director's Dealing (DIRS).
2008-09-07 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.